79 results on '"Tsakiridis, Theodoros"'
Search Results
2. Meta-Analysis of STereotactic body radiothERapy in non-spine BONE metastaseS (MASTER-BONES).
3. Prostate-Specific Membrane Antigen (PSMA) Expression Predicts Need for Early Treatment in Prostate Cancer Patients Managed with Active Surveillance
4. Disease control outcomes of stereotactic body radiation therapy or moderate hypo‐fractionation for prostate cancer: Real‐world experience at two Canadian centers
5. Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
6. 114 Stereotactic Body Radiation Therapy (SBRT) and Hypo-Fractionated Radiation Therapy (HFRT) Outcomes for Low and Intermediate-Risk Prostate Cancer (PRCA): Experience at Two Ontario Centres
7. Canagliflozin mediates tumor suppression alone and in combination with radiotherapy in non‐small cell lung cancer (NSCLC) through inhibition of HIF‐1α
8. The impact of staging FDG-PET/CT on treatment for stage III NSCLC - an analysis of population-based data from Ontario, Canada
9. GDF15 promotes weight loss by enhancing energy expenditure in muscle
10. 18F-DCFPyL (PSMA) PET as a radiotherapy response assessment tool in metastatic prostate cancer
11. Patterns of failure with 18F-DCFPyL PSMA PET/CT in the post-prostatectomy setting: A regional cohort analysis.
12. Biochemical disease control outcomes of stereotactic body radiation therapy (SBRT) or moderate hypo-fractionation (HFRT) for low- and intermediate-risk prostate cancer (PrCa): Retrospective analysis of 12 years of experience at two Canadian cancer centers.
13. Patterns of failure after radiotherapy (RT) in patients with prostate cancer re-staged with 18F-DCFPyL PSMA-PET: A regional cohort analysis.
14. Contemporary real-world radiotherapy outcomes of unresected locally advanced non-small cell lung cancer
15. Lung SBRT credentialing in the Canadian OCOG-LUSTRE randomized trial
16. 68: Radiation Dose, Technique, and Use of Brain Radiation on Overall Survival in Patients with Limited-Stage Small Cell Lung Cancer
17. Metformin-induced reductions in tumor growth involves modulation of the gut microbiome
18. Contemporary outcomes of a systematic prostate cancer active surveillance program: Results from the Niagara Health System, Ontario, Canada.
19. Salvage radiotherapy following HiFU : An institutional series and literature review
20. Metformin—A Thought-provoking Addition to Anticancer Therapies—Reply
21. The Journey of Radiotherapy Dose Escalation in High Risk Prostate Cancer; Conventional Dose Escalation to Stereotactic Body Radiotherapy (SBRT) Boost Treatments
22. Combined metformin-salicylate treatment provides improved anti-tumor activity and enhanced radiotherapy response in prostate cancer; drug synergy at clinically relevant doses
23. 18: PSMA-PET-Based Response Assessment of Metastatic Prostate Cancer Response to Radiotherapy: A Case Series
24. 100: The Role of FDG-PET in Staging and Treatment for Stage III NSCLC in Ontario between 2009-2017
25. 151: Prostate SBRT Boost Radiotherapy (PBS Trial): A Randomized Phase II Trial of SBRT Versus Conventionally-Fractionated Radiotherapy Boost Following Pelvic Radiotherapy in High-Risk Prostate Cancer
26. Tyrosine Kinase Inhibitor Therapy in Unresectable Locally Advanced NSCLC: Keep Holding Our Breaths or Time to Take a Breather?
27. Addition of Metformin to Concurrent Chemoradiation in Patients With Locally Advanced Non–Small Cell Lung Cancer
28. Metformin in Combination With Chemoradiotherapy in Locally Advanced Non–Small Cell Lung Cancer
29. 194: Cardiac Toxicity in Central Non-Small Cell Lung Tumours Treated with Stereotactic Body Radation Therapy (SBRT) - Is There A “No-Flutter Zone”?
30. A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The PBS Trial (NCT03380806)
31. Overall and chemotherapy‐free survival following stereotactic body radiation therapy for abdominopelvic oligometastases
32. Summary of international recommendations in 23 languages for patients with cancer during the COVID-19 pandemic
33. Patient and family support in the era of fake e-medicine: food for thought from an international consensus panel
34. Radiographic and metabolic evolution of prostate cancer lung metastasis detected by prostate-specific membrane antigen and fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography
35. 167 The New Diabetes Drug Canagliflozin Enhances the Response of Prostate Cancer to Radiotherapy
36. 40 Canagliflozin, a New Anti-Diabetic Agent Targeting Cellular Metabolism, Suppresses Survival and Enhances the Response of Non-Small Cell Lung Cancer (NSCLC) to Radiotherapy
37. 158 Impact of Pelvic Intensity-Modulated Radiotherapy (IMRT) on Lymph Node Coverage and Dose to Critical Organs, Compare to Three-Dimensional Conformal Radiation Therapy (3D-CRT), in Localized High-Risk Prostate Cancer
38. Initial reporting of NRG-LU001 (NCT02186847), randomized phase II trial of concurrent chemoradiotherapy (CRT) +/- metformin in locally advanced Non-Small Cell Lung Cancer (NSCLC).
39. Salicylate enhances the response of prostate cancer to radiotherapy
40. Inhibition of Acetyl-CoA Carboxylase by Phosphorylation or the Inhibitor ND-654 Suppresses Lipogenesis and Hepatocellular Carcinoma
41. Mechanisms of Metformin on Colon Cancer Inhibition: Roles of the Gut Microbiome, Butyrate and AMPK
42. Abstract 5850: Salicylate sensitizes prostate cancer (PrCa) to radiotherapy; activation of AMPK and suppression of lipogenesis
43. A Novel Neoadjuvant Therapy for Operable Locally Invasive Non–Small-Cell Lung Cancer. Phase I Study of Neoadjuvant Stereotactic Body Radiotherapy. LINNEARRE I (NCT02433574)
44. AMPK β1 reduces tumor progression and improves survival in p53 null mice
45. Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer
46. Targeting metabolism and AMP-activated kinase with metformin to sensitize non-small cell lung cancer (NSCLC) to cytotoxic therapy: translational biology and rationale for current clinical trials
47. Canadian Phase III Randomized Trial of Stereotactic Body Radiotherapy Versus Conventionally Hypofractionated Radiotherapy for Stage I, Medically Inoperable Non–Small-Cell Lung Cancer – Rationale and Protocol Design for the Ontario Clinical Oncology Group (OCOG)-LUSTRE Trial
48. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
49. 90: Combined Salicylate (SAL) - Metformin (MET) Treatment Induces Increased Tumour Suppression and Radiosensitization in Preclinical Models of Prostate Cancer (PRCA)
50. Metformin for chemo-radio-sensitization of NSCLC
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.